EUVIMEDEUVIMED entdecken
Crossref

Development of Natural‐Product‐Inspired ABCB1 Inhibitors Through Regioselective Tryptophan C3‐Benzylation

Dona Mariya Vincent, Habib Mostafa, Anza Suneer, Sabhashina Radha Krishnan, Mingmin Ong, Yoko Itahana, Koji Itahana, Rajesh Viswanathan iD

Chemistry – A European Journal · 2024

DOI: 10.1002/chem.202401782 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Chemistry – A European Journal, 2024. Verfasst von Dona Mariya Vincent und 7 weiteren Autor:innen. Beteiligte Einrichtung: Departments of Chemistry & Biology, Indian Institute of Science Education and Research, Tirupati, A. P., India. Hauptthemen laut MEDLINE: ATP Binding Cassette Transporter, Subfamily B, Tryptophan, Biological Products. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 53 Literaturangaben. Gefördert von: Science and Engineering Research Board, Directorate for Mathematical and Physical Sciences, National Medical Research Council.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The emergence of drug resistance in cancer cells eventually causing relapse is a serious threat that demands new advances. Upregulation of the ATP‐dependent binding cassette (ABC) transporters, such as ABCB1, significantly contributes to the emergence of drug resistance in cancer. Despite more than 30 years of therapeutic discovery, and several generations of inhibitors against P‐gp, the search for effective agents that minimize toxicity to human cells, while maintaining efflux pump inhibition is still underway. Leads derived from natural product scaffolds are well‐known to be effective in various therapeutic approaches. Inspired by the biosynthetic pathway to Nocardioazine A, a marine alkaloid known to inhibit the P‐gp efflux pump in cancer cells, we devised a regioselective pathway to create structurally unique indole‐C3‐benzyl cyclo ‐L‐Trp‐L‐Trp diketopiperazines (DKPs). Using bat cells as a model to derive effective ABCB1 inhibitors for targeting human P‐gp efflux pumps, we have recently identified exo‐ C3‐N‐Dbn‐Trp2 (13) as a lead ABCB1 inhibitor. This C3‐benzylated lead inhibited ABCB1 better than Verapamil. [21] Additionally, C3‐N‐Dbn‐Trp2 restored chemotherapy sensitivity in drug‐resistant human cancer cells and had no adverse effect on cell proliferation in cell cultures. For a clearer structure‐activity relationship, we developed a broader screen to test C3‐functionalized pyrroloindolines as ABCB1 inhibitors and observed that C3‐benzylation is outperforming respective isoprenylated derivatives. Results arising from the molecular docking studies indicate that the interactions at the access tunnel between ABCB1 and the inhibitor result in a powerful predictor for the efficacy of the inhibitor. Based on fluorescence‐based assays, we conclude that the most efficacious inhibitor is the p ‐cyano‐derived exo‐ C3‐N‐Dbn‐Trp2 (33 a) , closely followed by the p ‐nitro substituted analogue. By combining assay results with molecular docking studies, we further correlate that the predictions based on the inhibitor interactions at the access tunnel provide clues about the design of improved ABCB1 inhibitors. As it has been well documented that ABCB1 itself is powerfully engaged in multi‐drug resistance, this work lays the foundation for the design of a new class of inhibitors based on the endogenous amino acid‐derived cyclo ‐L‐Trp‐L‐Trp DKP scaffold.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

ATP Binding Cassette Transporter, Subfamily BTryptophanBiological ProductsHumansStructure-Activity RelationshipStereoisomerismDrug Resistance, NeoplasmDiketopiperazinesAntineoplastic AgentsAnimalsCell Line, TumorMolecular Docking SimulationIndoles

Stichwörter der Autor:innen

ABCB1 inhibitorsCompetitive inhibitionMultidrug resistanceNatural productspyrroloindoline alkaloids

Substanzen

ATP Binding Cassette Transporter, Subfamily BTryptophanBiological ProductsABCB1 protein, humanDiketopiperazinesAntineoplastic AgentsIndoles

Autor:innen und Institutionen

  • Departments of Chemistry & Biology, Indian Institute of Science Education and Research, Tirupati, A. P., India.
  • Programme in Cancer & Stem Cell Biology, Duke-NUS Medical School, 169857, Singapore, Singapore.

ORCID-Profile: Rajesh Viswanathan

Förderung

  • Science and Engineering Research Board
  • Directorate for Mathematical and Physical Sciences
  • National Medical Research Council

Zitieren

APA

Mariya Vincent, D., Mostafa, H., Suneer, A., Radha Krishnan, S., Ong, M., Itahana, Y., Itahana, K., & Viswanathan, R. (2024). Development of Natural‐Product‐Inspired ABCB1 Inhibitors Through Regioselective Tryptophan C3‐Benzylation. Chemistry – A European Journal. https://doi.org/10.1002/chem.202401782

Vancouver

Mariya Vincent D, Mostafa H, Suneer A, Radha Krishnan S, Ong M, Itahana Y, et al. Development of Natural‐Product‐Inspired ABCB1 Inhibitors Through Regioselective Tryptophan C3‐Benzylation. Chemistry – A European Journal. 2024. doi:10.1002/chem.202401782

BibTeX
@article{MariyaVincent2024,
  author = {Mariya Vincent, Dona and Mostafa, Habib and Suneer, Anza and Radha Krishnan, Sabhashina and Ong, Mingmin and Itahana, Yoko and Itahana, Koji and Viswanathan, Rajesh},
  title = {Development of Natural‐Product‐Inspired ABCB1 Inhibitors Through Regioselective Tryptophan C3‐Benzylation},
  journal = {Chemistry – A European Journal},
  year = {2024},
  doi = {10.1002/chem.202401782}
}
Kostenlos starten →